|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2005-1-5
|
|
pubmed:abstractText |
VIP receptor has been clarified to exist on immune cells, indicating its possible involvement in immunity and inflammatory response. Therefore, we investigated the effects of VIP and selective agonists for 2 subtypes of VIP receptor (VPAC1-R and VPAC2-R agonist) on acute pancreatitis.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Amylases,
http://linkedlifedata.com/resource/pubmed/chemical/Caerulein,
http://linkedlifedata.com/resource/pubmed/chemical/Cytokines,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-10,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-6,
http://linkedlifedata.com/resource/pubmed/chemical/Lipopolysaccharides,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Messenger,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Vasoactive Intestinal...,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Vasoactive Intestinal...,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Necrosis Factor-alpha,
http://linkedlifedata.com/resource/pubmed/chemical/Vasoactive Intestinal Peptide
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
1536-4828
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
30
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
62-70
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:15632701-Acute Disease,
pubmed-meshheading:15632701-Amylases,
pubmed-meshheading:15632701-Animals,
pubmed-meshheading:15632701-Caerulein,
pubmed-meshheading:15632701-Cytokines,
pubmed-meshheading:15632701-Interleukin-10,
pubmed-meshheading:15632701-Interleukin-6,
pubmed-meshheading:15632701-Lipopolysaccharides,
pubmed-meshheading:15632701-Male,
pubmed-meshheading:15632701-Mice,
pubmed-meshheading:15632701-Mice, Inbred BALB C,
pubmed-meshheading:15632701-Monocytes,
pubmed-meshheading:15632701-Pancreas,
pubmed-meshheading:15632701-Pancreatitis,
pubmed-meshheading:15632701-RNA, Messenger,
pubmed-meshheading:15632701-Receptors, Vasoactive Intestinal Peptide, Type II,
pubmed-meshheading:15632701-Receptors, Vasoactive Intestinal Polypeptide, Type I,
pubmed-meshheading:15632701-Severity of Illness Index,
pubmed-meshheading:15632701-Spleen,
pubmed-meshheading:15632701-Tumor Necrosis Factor-alpha,
pubmed-meshheading:15632701-Vasoactive Intestinal Peptide
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
VIP attenuation of the severity of experimental pancreatitis is due to VPAC1 receptor-mediated inhibition of cytokine production.
|
|
pubmed:affiliation |
Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
